Atlas Trials

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Clinical trial NCT03583424 · COMPLETED

Trial details

NCT number
NCT03583424
Sponsor
Ohio State University Comprehensive Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Marginal Zone LymphomaRefractory Non-Hodgkin LymphomaRefractory Transformed Indolent Non-Hodgkin Lymphoma
Start date
2018-09-10
Primary completion
2021-09-30
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.